
BCYC Stock Forecast & Price Target
BCYC Analyst Ratings
Bulls say
Bicycle Therapeutics has received positive feedback from key opinion leaders (KOLs) regarding its product candidate, BT1718, indicating a competitive edge over existing treatments such as Padcev, particularly in efficacy. The potential for a 40-50% increase in progression-free survival (PFS) relative to Padcev further supports the promising prospects for the company's oncology-focused pipeline. Additionally, the company's commitment to delivering safe and effective outcomes while maintaining lower system costs underscores its value proposition in the biopharmaceutical market, contributing to a favorable outlook on its stock.
Bears say
Bicycle Therapeutics PLC faces a significant negative outlook due to recent investor concerns regarding the efficacy and safety of its product candidate, BT1718, particularly in light of equivocal data that has contributed to a substantial 45% year-to-date decline in share price. Moreover, the company's shares are now trading below their cash value following updates from clinical trials, indicating a lack of investor confidence in the viability of its novel approach to drug development despite having an active molecule. Lastly, the potential for a 25% downside looms if further safety issues or poor efficacy outcomes arise, underscoring the precarious nature of its current market position.
This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.
BCYC Analyst Forecast & Price Prediction
Start investing in BCYC
Order type
Buy in
Order amount
Est. shares
0 shares